Navigation Links
PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Date:12/4/2009

ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is presenting results of a study demonstrating the effectiveness of Valortim® in an inhalation anthrax model in the New Zealand White (NZW) rabbit. The data are being presented during an oral session at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2009 / BARDA Industry Day being held in Washington, D.C., December 2-4, 2009.

"PharmAthene continues to advance its anthrax pipeline and work collaboratively with the U.S. Government to develop novel vaccines and therapies to address this potentially serious terrorist threat, which has a lethality rate approaching 100% in untreated individuals," commented David P. Wright, President and Chief Executive Officer. "Accumulating evidence suggests that our product, Valortim®, possesses important characteristics that may make it a strong choice for procurement in the Strategic National Stockpile for civilian biodefense, including: demonstrated efficacy in animal models as both a prophylactic and therapeutic for inhalational anthrax; the potential for direct and indirect killing of Bacillus anthracis, a mechanism of action not previously described for other monoclonal antibodies; and, efficacy at low doses."

Summary of Data Presented

In an oral presentation entitled, "Efficacy of Valortim® in the New Zealand White Rabbit Model for Inhalation Anthrax" Dr. Elizabeth Leffel, Director of Non-Clinical Sciences at PharmAthene presented the results from two separate studies where NZW rabbits were challenged with a targeted aerosolized dose of 200 times the median lethal d
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
2. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
3. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
7. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
8. Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics
9. Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
10. Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
11. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
(Date:7/30/2015)... 2015  NanoSmart Pharmaceuticals, Inc., a private pharmaceutical ... Orphan Drug Designation from the Food and Drug ... uses NanoSmart,s proprietary drug delivery platform. The drug ... treatment of Ewing,s sarcoma, a rare type of ... Drug Designation on the basis of a plausible ...
(Date:7/30/2015)... 2015 Flexpoint Ford, a private equity firm ... announced that it has entered into a partnership with ... to form Kastle Therapeutics, LLC (Kastle).  The new company, ... on acquiring, developing and commercializing pharmaceuticals targeted toward diseases ... select therapies already approved for marketing, as well as ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 2Flexpoint Ford Announces Partnership with Alan MacKenzie and Bryan Stuart to Form Kastle Therapeutics 3
... 22, 2011 United Seating & Mobility (USM) ... transaction with Central Kentucky Mobility (CKM) to acquire and merge ... for Lexington, Louisville, as well as central, eastern and southern ... team strengthens our position within a core market for us ...
... WOONSOCKET, R.I., July 22, 2011 CVS Caremark Corporation ... conference call on Thursday, August 4, 2011, at 8:30 ... second quarter 2011 financial results. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... will be broadcast simultaneously through the Investor Relations portion ...
Cached Medicine Technology:CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:7/30/2015)... ... July 30, 2015 , ... ... Biz Report, which takes a look at small, medium, and large businesses making ... business expert, conducted the business review and shared with viewers how DevExpress has ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality ... Bernardino, recently announced that the Centers for Medicare and Medicaid (CMS) have awarded its ... care providers. 24/7 Care At Home’s agency is one of three top Orange County ...
(Date:7/30/2015)... ... , ... The need for accessibility is never greater than when we find ... well as visiting friends and family during these critical moments, hospitals around the Pennsylvania ... powered by ChargeItSpot , a Philadelphia-based startup that recently secured a $4M Series ...
(Date:7/30/2015)... ... 2015 , ... OncLive®’s extensive roster of Strategic ... Cancer Center (JCCC) mutually agreed to collaborate on projects that promote groundbreaking ... groups will help spread the news about the center’s leading-edge cancer research, robust ...
(Date:7/30/2015)... ... 2015 , ... Zejax is a New Way of Training ... , World renown body weight trainer, Paul Ziachik, announces today that he ... a person’s training capability. , The American College of Sports Medicine states that ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... April 12 (HealthDay News) -- A new study finds that ... spending, which is more than twice as high as previous ... to prevent obesity, said the researchers from Cornell University in ... medical costs are $2,741 a year higher (in 2005 dollars) ...
... Toxoplasma gondii parasite, the cause of ... birth defects in the United States. The researchers used a ... of Allergy and Infectious Diseases (NIAID), part of the National ... that children acquire from their acutely infected mothers while in ...
... , Chapel Hill, NC In a paper published today ... University of North Carolina at Chapel Hill unveils the first ... measurement of the mechanism behind drug-resistant cancer and rational prediction ... in human tissues that play a key role in cell ...
... THURSDAY, April 12 (HealthDay News) -- More unmarried women who ... a new government report shows. Twenty-seven percent of births ... threefold increase from 1985, researchers from the U.S. Centers for ... births outside of marriage, one parent isn,t present. But our ...
... order to accurately identify skulls as male or female, ... how the characteristics of male and female skulls differ ... University shows that these differences can be significant, even ... The researchers looked at the skulls of 27 ...
... People who have Huntington,s disease are much less likely to ... a new study that suggests the diseases share a common ... Huntington,s had a 53 percent lower risk of being diagnosed ... Huntington,s disease, the lower cancer risk applies to the other ...
Cached Medicine News:Health News:Test links strains of common parasite to severe illness in US newborns 2Health News:Test links strains of common parasite to severe illness in US newborns 3Health News:Kinase test may yield big gains for drug-resistant cancers 2Health News:More Unmarried Couples Having Babies: CDC 2Health News:Study finds significant skull differences between closely linked groups 2Health News:Huntington's Disease Linked to Reduced Cancer Risk in Study 2
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... Advia Centaur delivers a new level of ... to integrate with any laboratory automation system. ... supplies. It is the only immunoassay system ... load samples; system runs without any additional ...
... fully automated, random access ... 50 assays available worldwide. ... marker, therapeutic drug, serology, ... can be performed on ...
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Medicine Products: